Abstract
The clinical spectrum of chronic lymphocytic leukemia (CLL) is highly variable in that some patients experience early progression whereas others have many years of quiescent disease. A variety of clinical features, including Rai or Binet stage and cellular or molecular markers, have been evaluated as predictors of disease progression and treatment response (JW Oncol Hematol Nov 13 2006). Now, investigators with the CLL Research Consortium (CRC) have assessed three of the most promising CLL biomarkers — CD38 protein positivity, zeta-chain–associated protein kinase (ZAP)-70 positivity, and immunoglobulin heavy-chain variable ( IgVH ) gene mutation status — to determine their relative utility in predicting aggressive …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
